I'm developing Broadcourse to expand capabilities in drug development.
Prior to this, I've enjoyed contributing to research in novel therapeutics for neurological pathologies and autoimmune disorders and developing spectroscopic techniques for quantitative chiral analysis in analytical chemistry. I've also managed software and hardware development in explosive detection systems with DHS. I studied chemistry and biochemistry at UVA. Previously, I developed a project in the consumer products sector producing distilled spirits.
Recent business interests include an initiative to formalize and introduce an option with a variable maturity date set to clinical trial readouts as an instrument for hedge investing in drug development pipelines.
Connect with me on LinkedIn or over email (charles dot edgar dot spivey at gmail dot com). I am currently based in Cambridge and New York.